Aksitech Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-01-2025
- Paid Up Capital ₹ 5.00 M
as on 11-01-2025
- Company Age 30 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2021)
- Profit -103.91%
(FY 2021)
- Ebitda -103.91%
(FY 2021)
- Net Worth -33.53%
(FY 2021)
- Total Assets -86.14%
(FY 2021)
About Aksitech Life Sciences
The Corporate was formerly known as Mucos Pharma (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Akshay Daftary and Gautam Daftary serve as directors at the Company.
- CIN/LLPIN
U24230MH1994PTC079029
- Company No.
079029
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jun 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aksitech Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akshay Daftary  | Director | 25-Feb-2017 | Current |
| Gautam Daftary | Director | 12-May-1997 | Current |
Financial Performance of Aksitech Life Sciences.
Aksitech Life Sciences Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 103.91% decrease in profit. The company's net worth observed a substantial decline by a decrease of 33.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aksitech Life Sciences?
In 2021, Aksitech Life Sciences had a promoter holding of 85.00% and a public holding of 15.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Siro Clinpharm Private LimitedActive 24 years 10 monthsAkshay Daftary and Gautam Daftary are mutual person
Palettier Retail Private LimitedActive 3 years 6 monthsAkshay Daftary and Gautam Daftary are mutual person
- Siro Medical Writing Private LimitedActive 2 years 5 months
Akshay Daftary and Gautam Daftary are mutual person
- Siro Clintech Private LimitedActive 2 years 5 months
Akshay Daftary and Gautam Daftary are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aksitech Life Sciences?
Unlock and access historical data on people associated with Aksitech Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aksitech Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aksitech Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
